FDx Advisors’s AbbVie ABBV Stock Holding History

FDx Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$435K	Buy	+1,998	New	+$443K	0.14%	106
2025 Q4	–	Sell	-2,481	Closed	-$541K	–	92
2025 Q3	$541K	Buy	2,481 +326	+15%	+$66.4K	0.16%	88
2025 Q2	$400K	Sell	2,155 -568	-21%	-$106K	0.12%	106
2025 Q1	$571K	Buy	2,723 +1	+0%	+$194	0.19%	80
2024 Q4	$484K	Sell	2,722 -48	-2%	-$8.82K	0.14%	98
2024 Q3	$547K	Sell	2,770 -105	-4%	-$19.6K	0.15%	98
2024 Q2	$493K	Sell	2,875 -24,723	-90%	-$4.1M	0.14%	100
2024 Q1	$5.03M	Sell	27,598 -8,576	-24%	-$1.48M	0.76%	31
2023 Q4	$5.61M	Sell	36,174 -11,397	-24%	-$1.66M	0.43%	55
2023 Q3	$7.09M	Sell	47,571 -31,387	-40%	-$4.61M	0.59%	40
2023 Q2	$10.6M	Sell	78,958 -9,808	-11%	-$1.44M	0.58%	38
2023 Q1	$14.3M	Hold	88,766	–	–	0.62%	39
2022 Q4	$14.3M	Buy	88,766 +13,224	+18%	+$2.03M	0.62%	39
2022 Q3	$10.1M	Sell	75,542 -8,184	-10%	-$1.17M	0.45%	50
2022 Q2	$12.8M	Sell	83,726 -2,398	-3%	-$366K	0.48%	48
2022 Q1	$14M	Sell	86,124 -30,494	-26%	-$4.43M	0.47%	42
2021 Q4	$15.8M	Buy	116,618 +5,005	+4%	+$591K	0.44%	50
2021 Q3	$12M	Buy	111,613 +668	+0.6%	+$76.3K	0.38%	53
2021 Q2	$12.5M	Buy	110,945 +17,042	+18%	+$1.92M	0.42%	47
2021 Q1	$10.2M	Buy	93,903 +6,045	+7%	+$647K	0.38%	58
2020 Q4	$9.41M	Buy	87,858 +8,566	+11%	+$823K	0.39%	59
2020 Q3	$6.95M	Buy	79,292 +12,389	+19%	+$1.17M	0.33%	74
2020 Q2	$6.57M	Buy	66,903 +27,642	+70%	+$2.43M	0.34%	70
2020 Q1	$2.99M	Buy	39,261 +20,838	+113%	+$1.77M	0.19%	102
2019 Q4	$1.63M	Sell	18,423 -7,208	-28%	-$598K	0.09%	172
2019 Q3	$1.94M	Sell	25,631 -21,192	-45%	-$1.45M	0.13%	134
2019 Q2	$3.4M	Sell	46,823 -5,488	-10%	-$431K	0.13%	136
2019 Q1	$4.22M	Buy	52,311 +10,355	+25%	+$847K	0.17%	109
2018 Q4	$3.87M	Sell	41,956 -23,725	-36%	-$2.09M	0.32%	55
2018 Q3	$6.21M	Sell	65,681 -539	-0.8%	-$51.1K	0.23%	77
2018 Q2	$6.13M	Sell	66,220 -8,247	-11%	-$805K	0.22%	82
2018 Q1	$7.05M	Sell	74,467 -11,966	-14%	-$1.31M	0.21%	88
2017 Q4	$8.36M	Sell	86,433 -47,953	-36%	-$4.52M	0.23%	80
2017 Q3	$11.9M	Sell	134,386 -8,554	-6%	-$651K	0.33%	57
2017 Q2	$10.4M	Sell	142,940 -40,243	-22%	-$2.71M	0.31%	60
2017 Q1	$11.9M	Sell	183,183 -5,169	-3%	-$325K	0.37%	53
2016 Q4	$11.8M	Buy	188,352 +73,779	+64%	+$4.5M	0.34%	60
2016 Q3	$7.23M	Buy	114,573 +24,471	+27%	+$1.58M	0.3%	59
2016 Q2	$5.58M	Buy	90,102 +6,890	+8%	+$420K	0.25%	75
2016 Q1	$4.75M	Buy	83,212 +47,021	+130%	+$2.62M	0.22%	88
2015 Q4	$2.14M	Buy	36,191 +5,306	+17%	+$306K	0.1%	173
2015 Q3	$1.68M	Sell	30,885 -31,086	-50%	-$2.02M	0.14%	142
2015 Q2	$3.91M	Buy	61,971 +17,671	+40%	+$1.15M	0.19%	94
2015 Q1	$2.6M	Buy	44,300 +7,555	+21%	+$456K	0.06%	262
2014 Q4	$2.4M	Sell	36,745 -16,276	-31%	-$1.03M	0.15%	121
2014 Q3	$3.06M	Sell	53,021 -11,094	-17%	-$616K	0.2%	96
2014 Q2	$3.62M	Buy	64,115 +47,890	+295%	+$2.51M	0.24%	81
2014 Q1	$834K	Buy	16,225 +7,187	+80%	+$363K	0.07%	288
2013 Q4	$475K	Buy	9,038 +427	+5%	+$21K	0.05%	374
2013 Q3	$385K	Buy	+8,611	New	+$382K	0.05%	358

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FDx Advisors's ABBV Position: Q1 2026 in Review

FDx Advisors opened a new position in AbbVie (ABBV) in Q1 2026: 1,998 shares worth $435K. The stake represents 0.14% of the portfolio and ranks #106 among its holdings. This is a return to the name: FDx Advisors previously reported a position in ABBV as recently as Q3 2025.

FDx Advisors first reported a position in ABBV in Q3 2013 and has held it in 50 quarters since. The position peaked at $15.8M in Q4 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

FDx Advisors held 1,998 shares of AbbVie worth $435K as of Q1 2026.
AbbVie was a new FDx Advisors position in Q1 2026.
AbbVie made up 0.14% of FDx Advisors's portfolio in Q1 2026, its #106 holding.
FDx Advisors first reported a position in AbbVie in Q3 2013 and has held it in 50 quarters since.
FDx Advisors's AbbVie position peaked at $15.8M in Q4 2021.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on FDx Advisors's 13F filing for Q1 2026, filed 1 May 2026.